共 50 条
Provincial variations in radiotherapy utilization as a measure of access: A pan-Canadian study
被引:5
|作者:
Chan, Jessica
[1
,2
]
Brown, Erika
[3
]
Dennis, Kristopher
[4
,5
]
Milosevic, Michael
[6
,7
]
Brundage, Michael
[8
]
机构:
[1] BC Canc, Dept Radiat Oncol, 600 West 10th Ave, Vancouver, BC V5Z 4E6, Canada
[2] Univ British Columbia, Dept Surg, Vancouver, BC, Canada
[3] Canadian Partnership Qual Radiotherapy, Toronto, ON, Canada
[4] Ottawa Hosp, Div Radiat Oncol, Ottawa, ON, Canada
[5] Univ Ottawa, Ottawa, ON, Canada
[6] Univ Toronto, Radiat Med Program, Dept Radiat Oncol, Princess Margaret Canc Ctr, Toronto, ON, Canada
[7] Univ Toronto, Dept Radiat Oncol, Toronto, ON, Canada
[8] Queens Univ, Canc Res Inst, Div Canc Care & Epidemiol, Kingston, ON, Canada
关键词:
Cancer;
Radiotherapy;
Access;
Utilization;
Canada;
RADIATION-THERAPY;
BREAST;
PROSTATE;
LUNG;
NEED;
D O I:
10.1016/j.radonc.2021.12.017
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
Background and purpose: Access to radiotherapy (RT) is a key component of a cancer control strategy. However, radiotherapy utilization (RTU) rates fall short of desired benchmarks in certain Canadian provinces. We aimed to describe provincial variations in RTU across Canada. Materials and methods: We calculated radiotherapy utilization ratios (RTUR) for each Canadian province from 2016 (RT case counts divided by incidence counts), by cancer type (all cancers, lung, breast, rectal, prostate) and treatment intent (curative, palliative) where data were available. Data were extracted from each provincial RT data repository, cancer registry and/or RT department. We compared RTURs descriptively across provinces and to Ontario benchmarks, and calculated an estimated national RTUR. In provinces with capacity for data linkage, RTURs were compared to a linked (patient-specific) method of calculating utilization, by linking each incident case to whether RT was received within 1 year of diagnosis (RTU-1 yr). Results: Excluding three provinces that included re-treatments, all-cancer RTURs ranged from 0.31 in Manitoba to 0.40 in Nova Scotia. The national all-cancer RTUR was 0.35, which was comparable to Ontario benchmarks (0.34). Larger variations were seen by cancer type, with an absolute difference in RTURs of 28% for lung cancers, 27% for breast cancers, 21% for rectal cancers, and 18% for prostate cancers. RTURs for nearly all provinces were below established Ontario benchmarks for each cancer type, except prostate cancer. RTURs over-estimated RTU-1 yr by at most 5%, except for prostate cancers where they over-estimated RTU-1 yr by up to 15%. Conclusions: RTU varies by province in Canada, and most notably by cancer subsite. More granular data at the regional level and by healthcare facility is required to further tailor strategies aimed at improving RT access. RTURs also serve as a reasonable surrogate for linked RTU, and both methods can contribute meaningfully to measure RTU depending on the context and data availability. (C) 2021 Elsevier B.V. All rights reserved.
引用
收藏
页码:122 / 126
页数:5
相关论文